Grant: Engage Grants Program
University of Manitoba
$25,000.00
Protective and therapeutic use of digestion resistant starch (MSPrebiotic?) in a pig model of experimental colitis
FY 2017-18
Summary
Emerging therapeutics are used to alleviate intestinal inflammation and microbial dysbiosis including dietarysupplies of prebiotics and probiotics. Digestion resistant starch (DRS) represents a diverse range of dietarycarbohydrates bypassing into the lower gut where it undergoes microbial fermentation. DRS has beeninvestigated in the past years for its effects on gut health via balancing the microbiota composition and shortchain fatty acid levels. It is speculated that DRS can reduce colitis symptoms and pathology throughmodification of the gut microbiota, possible regulation of local inflammatory cytokines and its effects onmucosal barrier system.MSPrebiotic Inc., a Manitoba-based global biotechnological company, has developed a popular potato DRSproduct named MSPrebiotic?. The company is seeking a project to optimize their recommendations foradministration of MSPrebiotic? either as a preventative and/or therapeutic tool for reducing gut inflammationand improving gut health.Here, we investigate the protective and therapeutic effects of DRS (MSPrebiotic?) in a pig model ofexperimental colitis. Pigs will receive 5 different treatments including 1) basal control diet, 2) colitis-inducingdiet (1% carrageenan gum), 3) DRS diet, 4) colitis-inducing diet for 2 weeks followed by introduction of DRSdiet (to measure therapeutic effect of DRS), and 5) DRS diet for 2 weeks followed by a colitis-inducing diet (tomeasure the protective effect of DRS). Fecal consistency and large intestine histology will be used as measuresof gastrointestinal inflammation. Blood samples will be analyzed for systemic inflammatory markers. Gutmicrobiota profile will be assed using 16S rRNA gene sequencing in-house followed by prediction offunctional capacity of the microbial community using PICRUSt. The outcome of this research will help thecompany to optimize their recommendations for the use of MSPrebiotic? as a preventative and/or therapeuticapproach for reducing gut inflammation and improving gut health.
Program
Engage Grants Program
Recipient
Location
Manitoba, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
521785-2017
Name nom
Khafipour, Ehsan
Department département
Animal Science
Organization id
19
Institution établissement
University of Manitoba
Province en
Manitoba
Province fr
Manitoba
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1555
Committee name en
Prairie Internal Decision Committee
Committee name fr
Comité de décision interne pour les Prairies
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
9000
Research subject group en
Medical sciences
Research subject group fr
Sciences médicales
Research subject en
Medical sciences
Research subject fr
Sciences médicales
Partie
1
Nb partie
1
Application title
Protective and therapeutic use of digestion resistant starch (MSPrebiotic?) in a pig model of experimental colitis
Keyword
NSERC
Application summary
Emerging therapeutics are used to alleviate intestinal inflammation and microbial dysbiosis including dietarysupplies of prebiotics and probiotics. Digestion resistant starch (DRS) represents a diverse range of dietarycarbohydrates bypassing into the lower gut where it undergoes microbial fermentation. DRS has beeninvestigated in the past years for its effects on gut health via balancing the microbiota composition and shortchain fatty acid levels. It is speculated that DRS can reduce colitis symptoms and pathology throughmodification of the gut microbiota, possible regulation of local inflammatory cytokines and its effects onmucosal barrier system.MSPrebiotic Inc., a Manitoba-based global biotechnological company, has developed a popular potato DRSproduct named MSPrebiotic?. The company is seeking a project to optimize their recommendations foradministration of MSPrebiotic? either as a preventative and/or therapeutic tool for reducing gut inflammationand improving gut health.Here, we investigate the protective and therapeutic effects of DRS (MSPrebiotic?) in a pig model ofexperimental colitis. Pigs will receive 5 different treatments including 1) basal control diet, 2) colitis-inducingdiet (1% carrageenan gum), 3) DRS diet, 4) colitis-inducing diet for 2 weeks followed by introduction of DRSdiet (to measure therapeutic effect of DRS), and 5) DRS diet for 2 weeks followed by a colitis-inducing diet (tomeasure the protective effect of DRS). Fecal consistency and large intestine histology will be used as measuresof gastrointestinal inflammation. Blood samples will be analyzed for systemic inflammatory markers. Gutmicrobiota profile will be assed using 16S rRNA gene sequencing in-house followed by prediction offunctional capacity of the microbial community using PICRUSt. The outcome of this research will help thecompany to optimize their recommendations for the use of MSPrebiotic? as a preventative and/or therapeuticapproach for reducing gut inflammation and improving gut health.